Type II Diabetes Abrogates Sex Differences in Endothelial Function in Premenopausal Women

Helmut O. Steinberg, MD; Giancarlo Paradisi, MD; Jessica Cronin, RN; Kristin Crowde, RN; Annette Hempfling, RN; Ginger Hook, RN; Alain D. Baron, MD

Background—Obesity is a more potent cardiovascular risk factor (CVRF) in men than in women. Because traditional CVRFs cannot fully account for this sex difference, we tested the hypothesis that compared with men, women exhibit more robust endothelial function independent of obesity and that this sex difference is abrogated by diabetes.

Methods and Results—We studied leg blood flow (LBF) responses to graded intrafemoral artery infusions of the endothelium-dependent vasodilator methacholine chloride (Mch) and the endothelium-independent vasodilator sodium nitroprusside (SNP) in groups of lean, obese (OB), and type II diabetic (DM) premenopausal women and age- and body mass index–matched men. LBF response to intrafemoral administration of L-NMMA, an inhibitor of nitric oxide synthase, was also assessed in normal men and women. Maximum LBF increments in response to Mch were 347±57% versus 231±22% in lean women versus men (P<0.05) and 203±25% versus 111±17% in OB women versus men (P<0.01), respectively. In DM, maximum LBF increments in response to Mch were 104±24% and 138±33% in women and men, respectively, (P=NS). LBF decrements in response to L-NMMA were 34.9±4.1% and 17.1±4.2% in women and men, respectively (P<0.01). The response to SNP was not different between sexes and groups.

Conclusions—Premenopausal nondiabetic women exhibit more robust endothelium-dependent vasodilation owing to higher rates of nitric oxide release than men. Given the protective vascular action of nitric oxide, this difference may partially explain the lower incidence of macrovascular disease in women. In premenopausal women, DM causes impairment of endothelial function beyond that observed with obesity alone and leads to endothelial dysfunction similar to that observed in DM men. These findings may help explain the similar rates of coronary artery disease and mortality in diabetic men and women. (Circulation. 2000;101:2040-2046.)

Key Words: endothelium ■ obesity ■ diabetes mellitus ■ sex

Obesity is considered an independent risk factor for macrovascular disease.1,2 Despite a higher prevalence of obesity in women,3 the incidence of macrovascular disease is significantly lower in premenopausal women than men even when matched for traditional cardiovascular risk factors (CVRFs). Obesity (particularly when centrally distributed) is characteristically accompanied by insulin resistance, which is associated with a cluster of CVRFs.4 Adding to the list of CVRFs, we recently reported impaired endothelium-dependent vasodilation (EDV) in healthy obese insulin-resistant subjects.5 On closer analysis of our data, we noted possible sex differences in EDV. Given the central role of the endothelium to modulate vascular tone, lipid peroxidation, smooth muscle proliferation and migration, and monocyte adhesion,6 sex differences in endothelial function could partially account for the sex differences in cardiovascular events previously noted. Therefore, we hypothesized that compared with men, women exhibit higher rates of basal nitric oxide (NO)-dependent blood flow and more robust EDV independent of obesity. Furthermore, because the mortality from macrovascular disease is 3- to 5-fold higher in type II diabetic women7,8 than in nondiabetic women and reaches coronary event rates similar to those of diabetic men, we reasoned that if endothelial dysfunction is in fact an important CVRF, both diabetic men and women would exhibit similar degrees of endothelial dysfunction. In other words, we hypothesized that type II diabetes abrogates differences in endothelial function between sexes.

We studied leg blood flow (LBF) changes in response to graded intrafemoral artery infusions of the endothelium-dependent vasodilator methacholine chloride (Mch) and the endothelium-independent vasodilator sodium nitroprusside (SNP) in groups of lean, obese (OB), and OB type II diabetic (DM) men and women. Furthermore, to assess NO-dependent vascular tone, we measured LBF changes in response to the inhibitor of NO synthase Nω-monomethyl-L-arginine (L-NMMA).
artery infusion of L-NMMA (Clinalfa), an inhibitor of NO synthase, dependent or endothelium-independent vasodilation, respectively. Basal NO-dependent vasodilation was assessed by an intrafemoral artery infusion of L-NMMA (Clinalfa), an inhibitor of NO synthase, at a dose of 16 μg/min for 15 minutes (2.0 mL/min). The responses to Mch, SNP, and L-NMMA were studied in separate groups.

Study Population
Study subjects were healthy, with normal cuff blood pressure. DM subjects were withdrawn from oral antidiabetic drugs ≥4 weeks before the study, and regular insulin was withheld stopped 1 week before the study, and regular insulin was withheld 4 weeks in men and ≥28 in women. Studies were approved by the Indiana University Institutional Review Board, and all volunteers gave informed consent.

Protocol
All studies were done after an overnight fast. A 6F sheath (Cordis Corp) was placed into the right femoral vein to allow the insertion of a custom-designed 5F double-lumen thermodilution catheter (Baxter Scientific, Edwards Division) to measure LBF. The right femoral artery was cannulated with a 5.5F double-lumen catheter to allow simultaneous infusion of substances and invasive blood pressure monitoring via a vital signs monitor (Spacelabs).

All hemodynamic measurements were obtained with the subjects in the supine position in a quiet temperature-controlled room. Baseline LBF and mean arterial pressure measurements were obtained after ≥30 minutes of rest after the insertion of the catheters. Rates of LBF were obtained with the thermodilution technique and calculated by a cardiac output computer (model 9520A, American Edwards Laboratories). During baseline, 24 LBF measurements were obtained at ~30-second intervals. During drug infusion, LBF measurements were begun 2 minutes after the onset of each dose, and 10 measurements were taken for each dose. Invasively determined MAP was recorded with every other LBF determination.

Graded intrafemoral artery infusions of Mch or SNP (Roche Laboratories) were administered at sequential doses of 2.5, 5.0, 7.5, 10.0, 12.5, and 15.0 μg/min (0.1 to 0.6 mL/min) or 1.75, 3.5, and 7.0 μg/min (0.25 to 1.0 mL/min) to assess stimulated endothelium-dependent or endothelium-independent vasodilation, respectively. Basal NO-dependent vasodilation was assessed by an intrafemoral artery infusion of L-NMMA (Clinalfa), an inhibitor of NO synthase.

Table 1. Demographic and Metabolic Characteristics of the Study Groups Receiving Graded Intrafemoral Artery Infusions of Mch

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th></th>
<th>Type II Diabetes</th>
<th></th>
<th></th>
<th>Type II Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lean</td>
<td>Obese</td>
<td>Lean</td>
<td>Obese</td>
<td>Lean</td>
<td>Obese</td>
</tr>
<tr>
<td>n</td>
<td>44</td>
<td>16</td>
<td>8</td>
<td></td>
<td>5</td>
<td>23</td>
</tr>
<tr>
<td>Age, y</td>
<td>33.5±1.0</td>
<td>34.1±1.8</td>
<td>39.1±2.1</td>
<td></td>
<td>34.4±3.4</td>
<td>33.9±1.8</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>23.2±0.4</td>
<td>32.5±0.9*</td>
<td>32.3±2.4*</td>
<td></td>
<td>21.5±1.4</td>
<td>36.3±1.6*</td>
</tr>
<tr>
<td>Percent body fat</td>
<td>17.5±0.8</td>
<td>32.0±1.1†</td>
<td>29.9±1.8‖</td>
<td></td>
<td>25.1±2.6</td>
<td>46.5±1.4*</td>
</tr>
<tr>
<td>Absolute body fat mass, kg</td>
<td>12.8±0.7</td>
<td>32.8±1.9‖</td>
<td>31.1±5.3*</td>
<td></td>
<td>14.1±2.5</td>
<td>45.7±2.9*</td>
</tr>
<tr>
<td>Waist/hip ratio</td>
<td>0.92±0.01</td>
<td>0.96±0.02</td>
<td>0.96±0.01</td>
<td></td>
<td>0.81±0.02</td>
<td>0.86±0.01</td>
</tr>
<tr>
<td>Fasting glucose, mg/dL</td>
<td>93.7±9.0</td>
<td>94.6±3.2</td>
<td>186.4±28.2†</td>
<td></td>
<td>87.8±1.1</td>
<td>91.9±2.2</td>
</tr>
<tr>
<td>Fasting insulin, μU/mL</td>
<td>6.4±0.5§</td>
<td>10.8±1.9</td>
<td>19.7±7.3‡</td>
<td></td>
<td>10.3±1.5</td>
<td>13.1±1.6</td>
</tr>
<tr>
<td>Mean arterial pressure, mm Hg</td>
<td>87±1†</td>
<td>97±2‡</td>
<td>106±6‡</td>
<td></td>
<td>87±2</td>
<td>95±2</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>163±5</td>
<td>189±8</td>
<td>193±11</td>
<td></td>
<td>158±15</td>
<td>163±6</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>107±8</td>
<td>164±29*</td>
<td>163±24*</td>
<td></td>
<td>77±19</td>
<td>84±5</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>45±2</td>
<td>33±3*</td>
<td>35±3*</td>
<td></td>
<td>49±3</td>
<td>41±2</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>101±14</td>
<td>111±9</td>
<td>131±8*</td>
<td></td>
<td>99±15</td>
<td>104±6</td>
</tr>
<tr>
<td>Fasting FFA, μmol/L</td>
<td>394±24‡</td>
<td>575±59‡</td>
<td>764±116‡</td>
<td></td>
<td>451±42</td>
<td>619±67</td>
</tr>
</tbody>
</table>

Values are mean±SD.
Statistics within sex groups: *P<0.05 vs lean; †P<0.05 vs lean and obese; ‡P<0.05 vs each other.
Statistics between men and women: §P<0.05 vs female group; |P|<0.01 vs female group.

Methods

Statistical Analysis
Comparison between groups was performed by factorial or repeated-measures ANOVA. When significant differences between groups were found by ANOVA, this was followed by post hoc testing with Fisher’s protected least significant difference test. Because basal LBF differed significantly between groups, changes in blood flow are expressed as percent change (%Δ) to adjust for differences at baseline. Univariate regression analysis between the maximum changes in LBF (ΔLBF) in response to Mch and other variables known to modulate this response was performed after transformation of ΔLBF to its square root. Statistical significance was accepted at a level of P<0.05. All results are shown as the mean±SEM.

Results

Mch Study: Endothelium-Dependent Vasodilation

Metabolic and baseline hemodynamic characteristics of the study group are shown in Table 1. As expected, the groups exhibited differences in these characteristics due to the presence of obesity and/or type II diabetes.

In the men, the increments in LBF (Figure 1A) were significantly reduced in the OB and DM subjects. Lean subjects exhibited a nearly 2-fold higher rise in LBF than both OB and DM subjects (P<0.01). Maximum LBF increments were 231±22%, 111±17%, and 138±33% in lean, OB, and DM, respectively (P<0.05 lean versus OB and DM). In the women, the increase in LBF (Figure 1B) was significantly reduced in OB and DM. However, although OB women had a significantly smaller response than the lean women, they still exhibited nearly twice the rise in LBF compared with DM (P<0.05). Maximum LBF increments were 347±57%, 203±25%, and 104±24% in lean, OB, and
DM, respectively ($P<0.01$ between all groups). These data indicate that obesity and type II diabetes are associated with impaired endothelial function. Matching OB and DM women for waist-to-hip ratio (data not shown) did not attenuate the difference in LBF responses.

To further demonstrate that sex differences exist in the vascular response to Mch, we compared the LBF increments in response to Mch between sexes according to their groups (lean, OB, and DM). Lean women exhibited $40\%$ more pronounced increases in LBF (Figure 2A) than lean men, and the maximal LBF response to Mch was $347\pm57\%$ versus $231\pm22\%$ in female and male subjects, respectively ($P<0.05$). OB women exhibited nearly twice the LBF increments in response to Mch than the OB men (Figure 2B), and the maximal LBF response to Mch was $203\pm25\%$ versus $111\pm17\%$ in female and male subjects, respectively ($P<0.01$). Matching OB men and women for absolute body fat mass (data not shown) did not alter the results. In contrast to lean and OB women, DM women exhibited responses to Mch similar to those of DM men (Figure 2C), and maximal increases in LBF in response to Mch were $138\pm33\%$ and $104\pm24\%$ ($P=NS$) in men and women, respectively.

These data indicate that EDV is modulated by sex and is more robust in nondiabetic premenopausal women than in nondiabetic men and that this sex difference is abrogated by diabetes.

Univariate analysis between maximum response to Mch and other factors known to determine endothelial function, such as indices of body fat content, blood pressure, age, and cholesterol, revealed that body mass index, percent body fat content, hip and waist circumference, absolute body fat mass, and free fatty acid (FFA) levels achieved statistical significance (Table 2). Exclusion of the diabetic subjects did not change the results of these analyses. Using multivariate or stepwise regression analysis did not alter this finding, indicating that body fat content, body fat distribution, and basal serum FFAs appear to be the most important determinants of endothelial dysfunction.

**L-NMMA Study: Basal NO-Dependent Vasodilation**

Metabolic and baseline hemodynamic characteristics of the study group are shown in Table 3.

In response to infrarenal L-NMMA, LBF decreased to $0.169\pm0.020$ and $0.187\pm0.025$ L/min in the male and female...
groups, respectively \((P<0.05\) versus basal, both groups). The fall in LBF in response to L-NMMA (Figure 3) was \(17.1\pm4.2\%\) and \(34.9\pm4.1\%\) in the male and female groups, respectively \((P<0.01)\), indicating that women exhibit higher rates of basal NO production even in the face of higher body fat content (Table 3).

### SNP Study: Endothelium-Independent Vasodilation

Metabolic and baseline hemodynamic characteristics of the study group are shown in Table 4. As expected, the groups exhibited differences in these characteristics due to the presence of obesity and/or type II diabetes.

In both men and women, the LBF response to SNP was comparable between lean, OB, and DM subjects (Figure 4A and 4B). No differences were found in the LBF response to SNP between men and women. These results indicate that endothelium-independent vasodilation is not modulated by sex or impaired by obesity or type II diabetes.

### Discussion

Obesity is an independent risk factor for macrovascular disease across sexes.\(^1\) However, despite higher incidence of obesity in premenopausal women, rates of macrovascular disease are lower in premenopausal women than in men. Interestingly, this sex difference, which normally vanishes after menopause,\(^11\) is rapidly lost in premenopausal DM patients, with cardiovascular disease reaching 2- to 5-fold higher rates than in nondiabetic women.\(^8\) In fact, women with type II diabetes, compared with age-matched nondiabetic women, exhibit 5-fold\(^7\) to 8-fold\(^12\) higher rates of death related to coronary artery disease, with event rates nearly identical to those observed in type II diabetic men. Traditional CVRFs cannot completely account for these sex differences in cardiovascular mortality.\(^13\)

The results of our study demonstrate that (1) NO-dependent basal vascular tone and EDV is enhanced in nondiabetic premenopausal women compared with men; (2) obesity/insulin resistance is associated with blunting of EDV in both sexes, and this effect is markedly more pronounced in men; (3) although type II diabetes in men does not further reduce EDV beyond that observed with obesity, diabetes in obese women causes impairment of EDV above and beyond that observed with obesity alone; and (4) diabetes was associated with similar endothelial dysfunction in women and men. Together, these results suggest that premenopausal women exhibit higher rates of NO production than men independent of obesity and that this sex difference is abrogated by type II diabetes. Moreover, obesity appears to have a more potent effect to diminish endothelial function in men than in women.

The increased effect of Mch in nondiabetic women could be due to (1) increased NO production/release, (2) increased NO action at the level of the vascular smooth muscle in the women, or (3) decreased NO action at the level of the vascular smooth muscle in the men. Differences in NO action between sexes are highly unlikely, because the effect of graded infranifemoral artery infusions of the exogenous NO donor SNP did not differ between sexes, indicating no differences in vascular smooth muscle cell responses to NO between sexes. Thus, our data indicate that the increased vasodilator response to Mch in nondiabetic premenopausal

---

### Tables

#### Table 2: Univariate Regression Analyses for the Relationship Between Maximum Response to Mch and Variables Known to Modulate This Response

<table>
<thead>
<tr>
<th>Variable</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass index</td>
<td>0.49</td>
<td>0.52</td>
</tr>
<tr>
<td>Waist circumference</td>
<td>0.39</td>
<td>0.43</td>
</tr>
<tr>
<td>Hip circumference</td>
<td>0.39</td>
<td>0.46</td>
</tr>
<tr>
<td>FFA</td>
<td>0.3</td>
<td>0.55</td>
</tr>
<tr>
<td>Mean arterial pressure</td>
<td>0.09</td>
<td>0.14</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>0.12</td>
<td>0.22</td>
</tr>
<tr>
<td>Fasting insulin</td>
<td>0.15</td>
<td>0.26</td>
</tr>
<tr>
<td>Age</td>
<td>0.18</td>
<td>0.21</td>
</tr>
</tbody>
</table>

All subjects including diabetics are included.

#### Table 3: Demographic and Metabolic Characteristics of the Study Groups Receiving Infranifemoral Artery Infusions of L-NMMA

<table>
<thead>
<tr>
<th>Variable</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>198±16</td>
<td>162±6</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>125±16</td>
<td>88±12</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>43±5</td>
<td>43±6</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>128±18</td>
<td>97±8</td>
</tr>
</tbody>
</table>

Values are mean±SD.

\(*P<0.01\) men vs women.
women is due, at least in large part, to increased production/release of NO.

Because vascular responses to muscarinergic agonists like Mch or acetylcholine are not mediated exclusively by the release of NO,14 other vasodilating factors may mediate some of the vascular response. One of these, the endothelium-dependent hyperpolarizing factor, has been shown to contribute more to EDV in female than male rat mesenteric arter-
ies.15 Therefore, differences in endothelium-dependent hyperpolarizing factor release or action could theoretically also partially explain the sex differences in EDV.

We also examined basal NO-dependent vascular tone by measuring LBF response to intrafemoral artery administration of L-NMMA, an inhibitor of NO. Nondiabetic women, compared with nondiabetic men, exhibited *2-fold greater LBF decrements in response to intrafemoral artery infusions of L-NMMA. These results indicate that women exhibit higher rates of basal NO production than men, as suggested by Forte et al,16 who measured whole-body NO production.

This difference in NO-dependent vascular tone is all the more significant because both sex groups were well matched for factors known to impair EDV, such as age,17 blood pressure,18 and FFA19 and cholesterol20 levels.

It is important to emphasize that, even when matched for body mass index, women tended to have significantly higher body fat content than men, which is consistent with other reports.21–23 Because obesity/insulin resistance has been shown by us5 and others24 to be associated with impaired EDV, such as age,17 blood pressure,18 and FFA19 and cholesterol20 levels.

The precise mechanism(s) for the enhanced NO-dependent endothelial vasodilation in premenopausal nondiabetic women is unknown. Obviously, sex differences in sex hormones may be one explanation for the differences in NO production/release. In endothelial cell cultures, estrogen, the predominant female sex hormone, has been shown to stimulate NO synthesis.25 Vascular strips from female rats were found to release more NO in response to acetylcholine than

<table>
<thead>
<tr>
<th>TABLE 4. Demographic and Metabolic Characteristics of the Study Groups Receiving Graded Intrafemoral Artery Infusions of SNP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Men</strong></td>
</tr>
<tr>
<td>n</td>
</tr>
<tr>
<td>Age, y</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
</tr>
<tr>
<td>Fasting glucose, mg/dL</td>
</tr>
<tr>
<td>Fasting insulin, μU/mL</td>
</tr>
<tr>
<td>MAP, mm Hg</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
</tr>
<tr>
<td>Fasting FFA, μmol/L</td>
</tr>
</tbody>
</table>

Values are mean±SD.
Statistics within sex groups: *P<0.01 vs both OB and DM; †P<0.05 vs OB; ‡P<0.05 vs both lean and OB.
Statistics between men and women: §P<0.001 vs female group.

Figure 4. LBF increments above baseline (%Δ) in response to graded intrafemoral artery infusions of endothelium-independent vasodilator SNP in lean, OB, and DM men (A) and in OB and DM women (B).
vascular strips from male rats.26,27 In humans, estrogen replacement restored the blunted blood flow response to acetylcholine in women who underwent ovariectomy28 and in postmenopausal women.29 These data suggest that estrogen may directly stimulate NO production/release in women. Conversely, the predominant male sex hormone testosterone (or other androgens) may cause decreased NO production/release, as suggested by Herman and colleagues.30 The independent contributions of estrogens and androgens to the control of endothelial function in normal and pathophysiological states remains to be fully elucidated.

In addition, differences in insulin sensitivity between men and women may also account for higher rates of NO production/release in women. Several reports have demonstrated that women display nearly 50% higher insulin sensitivity than men when matched for age and body mass index,22,23 suggesting that sex modulates the association between body fat content and insulin sensitivity. We3 and others24 have shown that insulin sensitivity correlates positively with the magnitude of the blood flow responses to Mch and L-NMMA. Therefore, the greater endothelial dysfunction observed in men may be secondary to the more reduced insulin sensitivity in men versus women.

The mechanism(s) by which obesity impairs EDV is not well understood. Obesity is associated with elevated FFA,31,32 and we have previously shown19 that elevation of FFA in lean insulin-sensitive subjects caused blunting of EDV. Furthermore, elevation of FFA in vitro33,34 decreases NO production in endothelial cells. We found that FFA levels and the maximum response to Mch were significantly and inversely related. Taken together, our findings suggest that elevation of FFA levels in OB and OB DM subjects may be causally related to the observed endothelial dysfunction.

It is important to note that the presence of diabetes causes a further impairment of EDV in women but not in men. This suggests that obesity alone caused a maximal reduction in EDV in men and a submaximal effect in women. The slightly higher LDL cholesterol levels in the diabetic women may account for a small proportion (10% to 20%) of the difference in the LBF response to Mch. At the very least, our data further suggest that obesity is sufficient to cause endothelial dysfunction associated with decreased NO release in men, whereas superimposed hyperglycemia is necessary to produce similar degrees of endothelial impairment in woman.

Finally, it is important to consider the clinical implications of our data. Assuming that endothelial dysfunction is important in the development of macrovascular disease,35 it follows that control of hyperglycemia would be expected to have only a modest effect to reduce macrovascular disease in men, because this intervention would have limited effects to improve insulin sensitivity (reverse insulin resistance) and thus would not benefit endothelial function. In contradistinction, therapeutic interventions to control hyperglycemia would be expected to have dramatic effects in premenopausal women, because this maneuver would be expected to greatly ameliorate endothelial function. Conversely, maneuvers directed at reducing both obesity/insulin resistance (weight loss, exercise, insulin-sensitizing drugs) and hyperglycemia would be expected to greatly reduce macrovascular disease in both men and women. In this context, it is interesting that the results of the UK Prospective Diabetes Study36 showed only marginal effects of glycemic control alone (without amelioration of insulin resistance) on macrovascular disease. Unfortunately, an analysis examining sex differences in these outcomes has yet to be presented.

In summary, obesity/insulin resistance is associated with impaired endothelial function (reduced NO release) in both sexes, but this effect is remarkably more pronounced in men. Given the vasoprotective properties of endothelium-derived NO, this relative preservation of endothelial function may explain, at least in part, the decreased incidence of hypertension and cardiovascular disease in nondiabetic premenopausal women. Importantly, the development of severe endothelial dysfunction in women with type II diabetes could explain the epidemiological finding that type II diabetic women and men display similar elevated cardiovascular risk.

Acknowledgments

This work was supported by grants DK-42469, MO1-RR750-19, and DK-20542 from the National Institutes of Health and a Veterans Affairs Merit Review Award. The authors wish to thank Joyce Ballard for her expert and invaluable help in preparing the manuscript and Keryl Holloway for her technical assistance.

References


Type II Diabetes Abrogates Sex Differences in Endothelial Function in Premenopausal Women
Helmut O. Steinberg, Giancarlo Paradisi, Jessica Cronin, Kristin Crowde, Annette Hempfling, Ginger Hook and Alain D. Baron

_Circulation_. 2000;101:2040-2046
doi: 10.1161/01.CIR.101.17.2040

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/101/17/2040

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/